Roswell Cancer Center praises Cuba´s VSSP cancer drug effectiveness

According to a collaborative effort among EPCCC researchers and Cuba´s Center for Molecular Immunology (CIM), it was created a new strategy to correct immune dysfunction in patients suffering from malignant tumors, the source said. 
The reports, which involved both lab studies and an early-phase clinical trial, showed that a new immune modulator (VSSP) can significantly reduce myeloid-derived suppressor cells (MDSC) among people with advanced kidney cancer.

Read More

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s